Epoxides from polyunsaturated fatty acids (PUFAs) are potent lipid mediators. In vivo stabilization of these epoxides by blockade of the soluble epoxide hydrolase (sEH) leads to anti-inflammatory, analgesic and normotensive effects. Therefore, sEH inhibitors (sEHi) are a promising new class of drugs. Herein, we characterized pharmacokinetic (PK) and pharmacodynamic properties of a commercially available potent sEHi 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU). Cell culture studies suggest its high absorption and metabolic stability. Following administration in drinking water to rats (0.2, 1, and 5 mg TPPU/L with 0.2% PEG400), TPPU's blood concentration increased dose dependently within the treatment period to reach an almost steady state after 8 days. TPPU was found in all the tissues tested. The linoleic epoxide/diol ratios in most tissues were dose dependently increased, indicating significant sEH inhibition. Overall, administration of TPPU with the drinking water led to systemic distribution as well as high drug levels and thus makes chronic sEH inhibition studies possible.
Introduction
Oxidative metabolites (called oxylipins) of long chain polyunsaturated fatty acids (PUFAs) are potent lipid mediators. While many research and commercial drugs have focused on the formation of oxylipins by cyclooxygenases (COX) and lipoxygenases (LOX) [1] , in recent years, research on the biology of oxylipins produced by cytochrome P450s (CYP) has increased. For example, 20-HETE, a product of arachidonic acid (ARA) by CYP4s, acts as a potent vasoconstrictor [2] . By contrast, conversion of PUFA by CYP2C, CYP2J and several other CYP families, predominantly lead to the formation of epoxy-fatty acids (EpFA) [3] . All double bonds of PUFAs can be epoxidized, and, at least for ARA, all possible regioisomers are biologically formed [3, 4] .
The biology of the epoxides of ARA (epoxy eicosatrienoic acids, EpETrEs or EETs) is well characterized, and has been summarized in several recent reviews [4] [5] [6] [7] . Maintaining EET levels has beneficial effects in animal models of hypertension, inflammation and pain. However, the molecular mechanisms of EpFAs are largely unknown. It seems that EpFAs have different targets in different tissues, including nuclear receptors [8] and large-conductance potassium (BK) channels [9] as well as NF-B [10] . In contrast to other potent eicosanoids, such as prostaglandins (PGs), no receptor for EpFAs has been found yet. Interestingly, not all EpFAs evoke the same physiological response. While both, EETs and epoxides derived from EPA, epoxy eicosatetraenoic acids (EEQs or EpETEs), are analgesic [11] only EETs promote angiogenesis [12] while DHA epoxides [13] block it in the models reported to date. Furthermore it is unclear if EpFAs act as such, or are further processed e.g., by 12-LOX to 12-Hydroxy-17(18)-EpETE [14] or their derivatives such as amides [15] , which could act as endocannabinoids.
Epoxy fatty acids are mostly degraded in vivo by soluble epoxide hydrolase (sEH; EC 3.3.2.10) to the corresponding diols [16] .
Consequently, blockade of the sEH leads to maintenance of epoxy-PUFA levels [4] . In fact, most of the current knowledge about the biology of EpFAs is based on sEH knockout/inhibition with/without epoxy-FAs or their stable analogs.
Starting from mechanistic transition-state analogs, more than 15 years of development of sEH inhibitors led to highly potent compounds with drug-like properties [4, 16] . The most promising class of compounds are 1,3-disubstituted ureas such as 1-(1-propanoylpiperidin-4-yl)-3-[4 -(trifluoromethoxy)phenyl]urea (TPPU) [17] , which possesses high potency, [17] [18] [19] and adequate water solubility thus allowing easy formulation for animal studies [20, 21] . sEHis are a promising class of new drugs, and their beneficial effects have been already described on animal models of hypertension [20, 21] , sepsis [19] and cardiac fibrosis [22] . For drug development, studies of pharmacokinectics (PK, absorption, distribution, metabolism and excretion) and oral bioavailability are crucial. Therefore, we investigated here both intestinal absorption and metabolic stability of TPPU using cell culture models and by a PK study in rats after administrating low-dose TPPU in drinking water. The study was focused on distribution and in vivo inhibition of sEH (pharmacodynamics) by TPPU.
Materials and methods

Chemicals
The sEHi TPPU, 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (Fig. 1D , Sigma # SML0750, Cayman # 11120) was synthesized in house as previously described [17] . HPLC grade acetonitrile (ACN), acetic acid (AcOH), methanol (MeOH) and polyethylene glycol 400 (PEG400) were from Fisher Scientific (Nidderau, Germany). Oxylipin standards and internal standards were obtained from Cayman Chemicals (local distributor: Biomol, Hamburg, Germany). Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine serum (FBS) and all cell culture reagents were purchased from Biochrom (Berlin, Germany). ␤-glucuronidase (GUS) and sulfatase from Helix pomatia (HP-2) and all other chemicals were from Sigma Aldrich (Schnelldorf, Germany).
Incubation with primary rat hepatocytes (metabolic stability)
Primary rat hepatocytes were prepared as previously described [23] . Briefly, the animal was perfused with oxygen saturated 2 mM EDTA buffer (37 • C, 40 mL/min) for 45 min through the portal vain. The liver was cut into small pieces and the gently scratched-off cells were filtered and washed. Hepatocytes were isolated by density gradient centrifugation at 800 × g for 5 min with a Percoll colloid (58%) gradient. 1 × 10 5 cells were platted in a 6-well dish (2 mL) and incubated for 4 h. Thereafter, medium and non-adherent cells were removed and the cells were incubated with TPPU (1 M and 10 M) in M199 medium (final DMSO concentration 0.1%). After 24 h the medium was collected and one aliquot was directly frozen until analysis. The other was incubated with GUS (10.000 U/mL) and sulfatase (700 U/mL) in 1 M acetate buffer (pH 5.0) and incubated for 24 h.
Caco-2 cell model (in vitro intestinal absorption)
A monolayer of Caco-2 cells (continuous cell line of heterogeneous human epithelial colorectal adenocarcinoma cells) was grown on permeable membranes ("ThinCerts", Greiner Bio One, Frickenhausen, Germany) with a pore size of 0.4 m and a growth area of 1.13 cm 2 within 23-27 days as described [24, 25] . Cell monolayers that exceeded a resistance of 300 cm −2 were incubated with either 1 M or 10 M of TPPU solution in DMSO on the apical side. Medium samples on the apical and basolateral side were collected and frozen immediately after 1, 3 and 6 h. The apparent permeability coefficient (P app ) was calculated for t = 1 h as described [24] [25] [26] [27] . In order to assure that TPPU does not compromise the integrity of the monolayer additional experiments were performed in the presence of Lucifer yellow (LY; 100 M in the apical compartment), a marker for paracellular diffusion and no LY could be detected in the basolateral chamber.
Preparation of drinking water (and chemical stability)
TPPU stock solutions were prepared by dissolving TPPU in PEG400 at a concentration of 0.1, 1, 2.5 and 5 mg/mL. At room temperature, up to 15 mg/mL yielded a clear and stable solution. Each drinking water solution was prepared by mixing 10 mL of the stock solution with tap water (pH 7.7, calcium 78 mg/L, sodium 28 mg/L magnesium 6.6 mg/L, chloride 45 mg/L, sulfate 95 mg/L) to a total solution volume of 5 L, yielding a final PEG400 concentration of 0.2%. Stability of TPPU was assessed using water solutions containing 0.2 mg of TPPU/L and 10 mg of TPPU/L in 750 mL polycarbonate animal water bottles (Bioscape, Castrop-Rauxel, Germany) that were kept at the animal facility. 100 L samples were taken at 1, 3, 6 and 8 days without shaking the bottle, and then directly mixed with ACN containing internal standard (1:1, v:v) and frozen until analysis.
Animal experiments
Six-week old male Sprague Dawley rats (n = 6) were obtained from Charles River Laboratories International Inc. (Sulzfeld, Germany) and kept in groups in type IV polycarbonate cages (Bioscape). Before starting the TPPU treatment, the animals were allowed to acclimatize in our laboratory for one week. The animals had access to standard chow (#1324 Altromin, Lage, Germany) and were kept at 23 • C, in 55% humidity and a 12-h light/dark cycle. Water was provided ad libitum containing 0.2% PEG400 with and without TPPU at a concentration of 0.2 mg/L, 1 mg/L and 5 mg/L during the treatment period (8 days). Before (0 h) and after 2 h, 4 h, 8 h, 1 d, 2 d, 4 d and 8 d, 10 L blood were sampled from the tail vain. The blood was directly mixed with 50 L deionzed water [28] and frozen until analysis. On day 8, the animals were sacrificed by cardiac puncture after anesthesia with xylazine/ketamine (66/5 mg/kg BW). Plasma and whole blood were sampled. Aliquots of whole blood (800 L) were incubated with LPS (1 g/mL) for 24 h and calcium ionophore A23187 (50 M) [29] for 5 min at 37 • C to stimulate oxylipin formation.
After blood collection the animal was directly perfused with 30 mL of ice-cold phosphate buffered saline (PBS). Brain, heart, spleen, kidney, liver and muscle (biceps femoris) tissues were collected and snap frozen. In addition, the gut was cleaned by perfusion from stool residuals and transferred to ice cold PBS, and proximal and distal colon sections were sampled [30] .
As an orthogonal model to monitor systemic effects on oxylipins by TPPU, a high dose (10 mg/kg BW) was administered at 0 h and 24 h by oral gavage (10 L/g BW) to male CD-1 mice (10 weeks) and blood was collected after 48 h by puncture from the retrobulbar venous plexus. All animal experiments were approved by the animal welfare service of the state of Lower Saxony (Oldenburg, Germany; 33.9-42502-04-13/1134, 28.05.2013).
LC-MS Analysis of TPPU and oxylipin concentrations
Quantification of TPPU was carried out by online solid phase extraction (SPE)-LC-MS as described [28] . Briefly the analog 1-(1-acetylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea was used as an internal standard (IS) at a final concentration of 300 nM. Liquid samples were mixed 1:1 (v/v) with IS in ACN and directly analyzed. Tissue samples were homogenized and extracted twice with 250 L ethyl acetate (EtOAc)/250 L water in a ball mill (25 Hz, 10 min, 22 • C, MM 400, Retsch, Haan, Germany). The dried EtOAc phase was reconstituted in 50 L ACN/water 1/1 (v/v). 5 L of the sample were injected and extracted on a HLB SPE column (1.0 mm × 50 mm, 25 m particle) (Waters, Eschborn, Germany) and separation was carried out on a Kinetex RP-PFP column (2.1 mm × 100 mm, 2.6 m particle, Phenomenex, Torrance, CA USA). TPPU and the IS were detected on a Micromass LC-Quattro (Waters) in selected reaction monitoring mode (SRM) following positive electrospray ionization (SI).
Quantitative targeted oxylipin metabolomics in plasma was carried out on a 1290 LC equipped with a Zorbax Eclipse Plus C 18 reversed phase column (2.1 mm × 150 mm, particle size 1.8 m, Agilent, Waldbronn, Germany) coupled to a 6500 QTRAP instrument (AB Sciex, Darmstadt, Germany) in scheduled selected reaction monitoring mode following negative electrospray ionization (ESI) [31] . Instrument control was performed with Analyst 1.6.2 and data analysis was carried out with Multiquant 2.1.1 (AB Sciex) as described. For oxylipin analysis 250 L of plasma were extracted on 60 mg Oasis HLB (Waters) or 500 mg SepPak tC18 cartridges (Waters) as previously described [31] .
Effects of TPPU on tissue lipids were analyzed by online-SPE-LC-MS on a 6500 QTRAP instrument [32] simultaneously determining the linoleic acid metabolites 9(10)-epoxy octadecenoic acid (EpOME), 12(13)-EpOME, 9,10-dihydroxy octadecenoic acid (DiHOME) and 12,13-DiHOME. Utilizing 2 H 4 -9(10)-EpOME and 2 H 4 -9,10-DiHOME as internal standards (final concentration of 20 nM), concentrations in tissues were determined in the EtOAc extracts (see above) and the epoxide/diol ratio was calculated as sum of EpOMEs/DiHOMEs.
Results
Cell culture models
In the Caco-2 cell permeability assay, TPPU rapidly passes the cell monolayer, suggesting it will have a good intestinal permeability ( Fig. 1A-C) . Only a minor portion of the compound was found in the cells and after 6 h of incubation 66% of the added amount was detected on the basolateral side. Based on the flux after 1 h, a consistent apparent permeability coefficient (P app ) of 5.5 × 10 −5 cm/s was calculated for incubations containing 1 M and 10 M of TPPU (Fig. 1C) .
Metabolic stability of TPPU was investigated by incubating TPPU with rat hepatocytes (n = 6). After 20 h, 87 ± 3.5% of the initially added 1 M TPPU, and 90 ± 1.6% for 10 M, remained intact. Treating the medium after incubation with glucuronidase/sulfatase did not change the concentrations of TPPU (recovery 93 ± 9.3% (1 M) and 90 ± 5.9% (10 M)), suggesting no relevant direct phase II metabolism.
In vivo pharmaceutical properties and tissues distribution
Before testing in animals, we first assessed the stability of the compound during the course of the experiment (8 days). The chemical stability of TPPU in water was assessed, under realistic conditions inside the animal facility, in plastic water bottles at a low concentration of 0.2 mg/L and a high concentration of 10 mg/L (both 0.2% PEG400 in water). TPPU concentrations remained stable over a period of 8 days, with a recovery of 103 ± 3.2% for 0.2 mg/L and 109 ± 4.9% for 10 mg/L, respectively (Fig. S1) . The PK of TPPU was then tested in animals. Administration of TPPU with the drinking water at a concentration of 0.2, 1 and 5 mg/L (0.2% PEG400) changed neither the water consumption nor the body weight gain nor the behavior of the animals (Table S1 ). Following administration of the drinking water, the TPPU blood concentration increased rapidly ( Fig. 2A, Fig. S2 ) in a dose-dependent manner over 24 h. After 8 days, a steady state was reached at blood concentrations of 31 ± 3.4 nM (11 ± 1.2 ng/mL; 0.02 mg/kg BW), 188 ± 22 nM (68 ± 7.9 ng/mL; 0.1 mg/kg BW) and 877 ± 47 nM (320 ± 17 ng/mL; 0.5 mg/kg BW). However, TPPU concentration in plasma was significantly lower, suggesting its absorption into the blood cells ( Fig. 2B and C) .
TPPU was distributed in all tissues investigated (Fig. 2D) . The compound reached similar levels in spleen, kidney and heart (30-700 pmol/g (11-250 ng/g), Fig. 2D ). In the group with the highest TPPU concentration the liver tissue levels were about 3.5-fold higher in comparison to the heart tissue. TPPU levels of the other treatment groups were comparable in heart and liver tissue. In the intestinal tissue, concentrations were slightly lower, probably because of the higher amount of connective tissue in the investigated colon preparations. For plasma, whole blood and all tissues, the reached levels showed a remarkable linear relation of the TPPU concentration to the administered dose (Fig. 2B-D) . 
In vivo inhibition of sEH
The target engagement of TPPU was assessed based on the plasma epoxide to diol ratios of PUFAs (Fig. 3 ) [6, 12, 13, [19] [20] [21] [22] 33, 34] . The concentrations of all oxylipins determined in rat plasma are shown in Table S2A and B. Analytes covered by the LC-MS method which did not exceed the LOQ are displayed in Table S3 . Eight days administration of TPPU with the drinking water (0.02, 0.1 and 0.5 mg/kg BW/day) did not change the plasma epoxide/diol ratio of most n3-and n6-PUFAs (Fig. 3) . However, a dose dependent increase was observed for the EpOME/DiHOME ratio, which was most pronounced for 12(13)-EpOME/12,13-DiHOME (Fig. 3) . that the solid phase extraction technique massively influences the determined epoxy-PUFA levels [31] -led to consistent results (SI Table S2A and B, Fig. S3 ). In order to compare the results to previous studies investigating changes in sEH activity by TPPU [19] [20] [21] , effects of a 20-fold higher dose were tested in an acute exposure model. TPPU at 10 mg/kg BW administered twice via oral gavage to mice (at 0 h and 24 h) resulted in plasma TPPU concentrations of 1800 ± 500 nM after 48 h and led to significant shifts in the epoxide/diol ratios of all PUFAs (Fig. 4) .
Following ex vivo activation of lipases and enzymes of the ARA cascade in blood cells by treatment with calcium ionophore (50 M for 5 min), led to a reduction of most epoxide levels while diol levels were comparable to inactivated samples (Tab. S2B and C). This led overall to a reduction of epoxide/diol ratios (Table S2B and C and Fig. S4 ). However, following treatment with LPS (1 g/mL for 24 h), most epoxide levels were slightly and diol concentrations were strongly elevated in comparison to the inactivated samples leading to reduced epoxide/diol ratios (Table S2B and 5 . Epoxy-linolenic acid to dihydroxy-linolenic acid ratios as marker for sEH activity in tissues following 8 day administration of TPPU to male SD rats. All results are shown as mean ± SE (n = 6, one-way ANOVA followed by Tuckey test, ***p < 0.001, **p < 0.01, *p < 0.05). S5). Moreover, observed effects of TPPU were much stronger for linoleic acid (LA) and ALA metabolite ratios, especially for 12(13)-EpOME/12,13-DiHOME and 12(13)-EpODE/12,13-DiHODE.
The modulation of sEH activity in tissues after oral treatment via the drinking water was investigated based on the EpOME/DiHOME ratio (Fig. 5) . In heart, skeleton muscle, brain and proximal colon a dose dependent increase of the EpOME/DiHOME ratio was observed, being most pronounced in the heart (17-fold control vs. 0.5 mg/kg BW/day). In this tissue, even the lowest dose tested (0.02 mg/kg BW/day) led to a pronounced elevation of the epoxide to diol ratio (Fig. 5 ).
Discussion
In the present work, we present details on pharmacokinetics and pharmacodynamics of the potent sEHi, TPPU. With a molecular weight of 359 Da, six hydrogen bond acceptors and two hydrogen bond donors as well as an n-octanol/water coefficient of 2.4 ± 0.5 [17] , it fulfills all criteria of Lipinski's rule of five [35] of a drugable compound. Moreover, the potency to inhibit sEH is high (human IC 50 0.9 nM; rat 5 nM and mice IC 50 6 nM [36] ) and TPPU has been successfully used in several animal disease models such as LPS induced sepsis [19] and cardiac fibrosis [22] in mice.
In the Caco-2 cell model, TPPU efficiently traverses through the intestinal barrier with an observed P app of 5.5 × 10 −5 cm/s. This value suggests that absorption should not be a limiting factor for the oral bioavailability of TPPU [26, 27] . This is consistent with the observed bioavailability of TPPU (31-41%) when administered by oral gavage (0.1-3 mg/kg) in mice, based on the area under the curve (AUC) [19] .
Another major factor limiting oral bioavailability and in vivo potency of a drug is its metabolism (first pass effect) [37] . TPPU shows good metabolic stability when incubated with primary rat hepatocytes. It is interesting that apparently no direct phase II conjugation by liver glucuronosyltransferases takes place, though the direct N-glucuronidation has been described for the structurally similar triclocarban [38] . Moreover, TPPU seems to be stable by phase I metabolism since 90% of TPPU was remained in the medium of primary rat hepatocytes after 20 h of incubation. This metabolic stability may provide one mechanistical explanation for the long half-life/mean residence time of more than 24 h for TPPU after a single dose by p.o. or i.v. administration [19] .
For long-term treatment, oral gavage as well as sub-cutaneous injections are not favorable. The resulting stress could have an influence on the animal model. Moreover, tissue injury and inflammation, particularly of the esophagus after oral gavage, can lead to artifacts and loss of animals. Administration with the drinking water circumvents these problems. Consistent with an earlier report [39] , TPPU could be well formulated in water using PEG400 as primary solvent. The resulting solution with 0.2% PEG400 in the drinking water was stable under realistic conditions in the animal facility. Over a period of 8 days, no concentration change of TPPU was observed. Moreover, TPPU in a concentration of 0.2-5 mg/L did not change the drinking behavior of the animals and no apparent signs of changed physiology or toxicity (altered body weight gain, health status) were observable after 8 days of treatment.
As commonly expected for a rat on a dry pellet diet, the animals drank about 10% of their body weight per day. Thus, TPPU concentrations in the drinking water can be easily translated to daily oral doses (10% of water concentration) over the whole dose range tested (0.02, 0.1 and 0.5 mg/kg BW/d). Because of the long halflife of TPPU [19] , its concentration increased during the treatment period. However, after 8 days an almost plateau of mean 31 ± 2.4, 188 ± 20, 877 ± 47 nM was reached in blood. The observed blood concentrations were similar to mice between a single dose (p.o.) of TPPU (C max = 270 nM and 1700 nM at doses of 0.1 mg/kg and 0.3 mg/kg, respectively) [19] and 8-12 day drinking water treatment (C max = 200-1500 nM at doses of 0.02-0.2 mg/kg BW) [21] . A single oral dose (0.3 mg/kg) led to similar C max (700 ± 600 nM) in cynomolgus monkeys [18] , indicating that it might be possible to extrapolate these data to larger animals.
An excellent linearity between the administered dose and the blood levels was found, allowing to precisely adjusting the systemic TPPU levels by drinking water concentration. With a log P of 3.5 [17] , TPPU concentrates in the (more lipophilic) cellular fraction of whole blood resulting in a 2-fold lower plasma concentration. Interestingly, this distribution is comparable to the much less polar sEHi triclocarban [40] .
Consistent with its high flux through the Caco-2 monolayer and the short alpha half-life in a two component model after i.v. administration (indicating distribution) [19] , TPPU freely diffuses through membranes and a distribution in all investigated tissues was found. However, despite the high fat content of the brain, the levels were slightly lower than in other tissues, maybe due to an active efflux transport. Highest concentrations were found in liver, spleen, heart and kidney (dose 0.5 mg/kg BW: 0.50-2.4 nmol/g (0.18-0.86 g/g)).
Ulu et al. found after three weeks administration of TPPU in the drinking water to mice at the same daily doses (0.2 and 0.6 mg/kg BW) kidney concentrations of 7 ± 0.8 g/g (20 ± 2 nmol/g) and 33 ± 0.8 g/g (91 ± 2 nmol/g) [39] . The observed plasma levels were with 610 ± 130 nM and 1800 ± 445 nM also 100-fold higher than in our study. These concentrations are in the same range as observed in our experiments following two days treatment with 10 mg/kg BW administered by oral gavage (1800 ± 300 nM TPPU in plasma). Thus, three weeks chronic treatment with TPPU in the drinking water could lead to a stronger accumulation of TPPU in blood and tissues than indicated by the kinetics of the eight-day-treatmentperiod reported here.
Target engagement of TPPU treatment with the drinking water was investigated with respect to its intended mode of action, inhibition of the sEH. As commonly carried out [11] [12] [13] [18] [19] [20] [21] 33, 34] , the epoxy-FA to diol ratio was used as biomarker of in vivo sEH activity. Though plasma and blood concentrations of TPPU are higher than its IC 50 value (6 nM for the rat sEH) [36] , only moderate or no effects on the epoxide to diol ratios of LA, ALA, ARA, EPA and DHA were observed. Using an alternative sample preparation method [31] yielded the same result (SI). Only the 12(13)-EpOME/12,13-DiHOME and the overall EpOME/DiHOME ratio in plasma were increased in a dose-depend manner. By contrast, two-day treatment by oral gavage (10 mg/kg) in mice expressing much higher amounts of sEH in the liver [42] led to the expected dramatic increase in the epoxide/diol ratio of all PUFAs. Ex vivo activation of the freshly drawn blood boosted the detected concentration of oxylipins. However, even under these conditions, mimicking an activation of the ARA cascade, no or only moderate effects of TPPU treatment on epoxide/diol ratios (except for LA and ALA oxylipins with LPS treatment) were observed.
8-day administration of up to 5 mg/L TPPU in the drinking water does not change the epoxide/diol ratios in plasma. This ratio, which is commonly used for target engagement of sEH inhibition [33, 34] , is thus of little help for the investigation of possible effects of low oral doses of TPPU. Consistently, other studies giving TPPU doses below 1 mg/kg BW to monkeys (0.3 mg/kg BW) [18] and mice [21] , did not find an effect on the epoxide/diol ratio of most PUFA in plasma. As in our study, the EpOME/DiHOME ratio was strongest increased among all PUFA. Consequentially, using this ratio as biomarker for sEH activity, we found massive effects of all administered doses in tissues, except for liver. Particularly in the heart, expressing high amounts of EET forming CYP2J2 [41] , even a dose as low as 0.2 mg/kg BW led to an increase in the epoxide/diol ratio. In the kidney, a moderate increase in the EpOME/DiHOME ratio was observed, which is in line with the effects of TPPU (0.2-0.6 mg/kg BW) in an angiotensin II hypertension model [20, 21] . The sEHi activity in rat liver is very low compared to other species, such as mice or rabbits [42] . This might be one explanation that no effect of TPPU on the EpOME/DiHOME ratio in the liver was observed.
Conclusion
The potent sEH inhibitor TPPU shows high metabolic stability, is intestinally efficiently absorbed and can be stably formulated in the drinking water. Moreover, the water concentrations correlate excellently with the resulting plasma and tissues levels of the compound. Besides having concentrations well above IC 50 concentration of TPPU, the epoxide/diol ratios, the most commonly used marker for sEHi target engagement, were not changed in the plasma but increased for EpOMEs dose-dependently in some tissues. Though EpOMEs are not believed to significantly contribute to the biology of epoxy-ARA, such as anti-inflammatory, vasodilatory and analgesic effects, these results clearly suggest that the treatment with low doses of TPPU with the drinking water led to systemic sEH inhibition. If this is sufficient to cause a biological/physiological response will clearly depend on the physiological function/disease investigated. Some models might require a higher dose of TPPU to elicit a significant sEH inhibition in the targeted organ. < 100 # < 100 # < 100 # < 100 # < 100 # < 100 # < 100 # < 100 # < 100 #
